Cheryl Cox Kinney, MD, explains when night sweats warrant further evaluation, including red flags, persistent symptoms, and potential nonmenopausal causes.
Commentary|Videos|August 31, 2023
3 Dangerous Respiratory Viruses, 3 Robust Vaccines, 3 Shots at Broad Protection This Year
Author(s)Grace Halsey
Advertisement
"I'm gonna go for it. I'm going for all 3," said family physician Chuck Vega, MD, referring to the 3 vaccines that will be available against the potential "tripledemic" viruses in the 2023-2024 respiratory virus season: SARS-CoV-2, respiratory syncytical virus (RSV), and influenza.
Vega practices in Irvine, CA, where many of his patients are frail older adults with "7 or 8 chronic illnesses," and endless medication lists, he told Patient Care® recently. The good news is that this is also a population that historically is not resistant to vaccination. While the shared decision making that will accompany a recommendation for the RSV shot may take some extra time, Vega is all in, as he explains in this short video.
William Schaffner, MD, is professor of infectious disease and preventive medicine in the Department of Health Policy, and professor of medicine in the Division of Infectious Diseases at Vanderbilt University School of Medicine in Nashville, TN.
Charles Vega, MD is health sciences clinical professor and associate dean for Diversity and Inclusion at the UC Irvine School of Medicine where he also serves as executive director for the UC Irvine Program in Medical Education for the Latino Community.
For other conversations in our series with Drs William Schaffner and Chuck Vega:
Advertisement
Related to this article
TMS 2026: Menopause was coded in just 7.8% of midlife outpatient visits. Arina Chesnokova, MD, MPH, discusses diagnosis gaps, prescribing risks, and solutions for primary care.
Investigational CagriSema produced 23.1% to 26.7% weight loss across menopause stages at 68 weeks, with improvements in cardiometabolic risk factors.
An EHR-integrated tool matched manual CKD and cardiovascular risk assessments in 60 patients and showed promise for improving risk-based kidney care in primary care.
TMS 2026: Nearly 67% of US women receiving elinzanetant achieved at least a 50% reduction in menopausal VMS frequency by week 12 in pooled phase 3 trial data.
TMS 2026: Only 21.7% of women initiated menopause hormone therapy, with significant racial disparities and low treatment persistence, a new study finds.
TMS 2026: OB/GYN visits had nearly 4-fold higher odds of menopause coding than family medicine visits, with disparities by race and insurance, a study found.
JoAnn Pinkerton, MD, discusses new research she presented at The Menopause Society 2026 Annual Meeting on elinzanetant for menopausal vasomotor symptoms.
Advertisement
Advertisement
Trending on Patient Care Online
1
Menopause Care in Primary Care: Closing Diagnosis and Treatment Gaps
2
Primary Care Lens: Atrial Fibrillation From Detection to Referral in Primary Care
3
CagriSema Cuts Weight Up to 27% Across Menopause Stages: TMS 2026
4
Night Sweats in Midlife Women: A Q&A With Cheryl Cox Kinney, MD
5